BioNTech SE (BNTX) Common Equity (2018 - 2025)

BioNTech SE has disclosed Common Equity across 8 years of filings, most recently posting $22.4 billion for Q4 2025.

• Common Equity for Q4 2025 came in at $22.4 billion, up 7.88% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.4 billion (up 7.88% YoY), and the FY2025 annual result was $21.7 billion, up 4.71% from the prior year.
• Common Equity came in at $22.4 billion for Q4 2025 at BioNTech SE, up from $21.6 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $22.4 billion in Q4 2025 to a low of $3.0 billion in Q1 2021.
• The 5-year median for Common Equity is $20.6 billion (2024), against an average of $18.2 billion.
• Across the five-year window, Common Equity surged 895.88% in 2021 and declined 8.22% in 2025, its largest moves.
• BioNTech SE's Common Equity stood at $13.6 billion in 2021, then jumped by 50.39% to $20.5 billion in 2022, then increased by 6.46% to $21.8 billion in 2023, then dropped by 4.78% to $20.7 billion in 2024, then climbed by 7.88% to $22.4 billion in 2025.
• The last three Common Equity figures came in at $22.4 billion (Q4 2025), $21.6 billion (Q3 2025), and $20.9 billion (Q2 2025), per Business Quant data.